Jade Biosciences widens Q3 2026 loss to $35.1 million; cash stands at $475.7 million
Jade Biosciences posted a $35.1 million net loss for Q3 2026 versus $25.2 million a year earlier, with $475.7 million in cash, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Jade Biosciences reported a net loss of $35.1 million for the third quarter of 2026, compared with $25.2 million a year earlier, according to TradingView's summary of the company's SEC filing.
Research and development spending rose to $30.8 million from $22.0 million, while general and administrative costs climbed to $8.8 million from $5.4 million. The operating loss reached $39.6 million versus $27.4 million. The loss per share was $0.42, down from $0.48 a year earlier.
As of September 30, 2026, cash, equivalents and investments stood at $475.7 million. The company believes this balance will cover operations and capital spending until late 2028. It plans to start a Phase 3 study of JADE101 in IgA nephropathy and a Phase 1 study of JADE301 in healthy volunteers, both in Q4 2026. Interim JUNIPER data for the Phase 2 program is due in Q2 2027. Brad Dahms also took on a broader role as CFO and Chief Business Officer, covering business development and corporate strategy.
why it matters
Rising losses alongside higher R&D spending are typical for clinical-stage biotechs. The sizable cash reserve eases near-term funding pressure, while investors will watch the 2027 data readouts.
tags
instruments
sources
- Jade Biosciences Reports Q3 2026 Net Loss of $35.1 Million, Cash of $475.7 Million — TradingView, 13 November 2026 at 12:23 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗